Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +4.65% 11.25p 11.00p 11.50p 12.50p 9.50p 12.00p 11,418,946 16:22:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.2 -0.5 -0.8 - 6.61

Physiomics (PYC) Latest News

More Physiomics News
Physiomics Takeover Rumours

Physiomics (PYC) Share Charts

1 Year Physiomics Chart

1 Year Physiomics Chart

1 Month Physiomics Chart

1 Month Physiomics Chart

Intraday Physiomics Chart

Intraday Physiomics Chart

Physiomics (PYC) Discussions and Chat

Physiomics Forums and Chat

Date Time Title Posts
16/12/201711:05PHYSIOMICS plc Virtual Tumor platform4,859
16/12/201710:59Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni20
01/12/201719:18RGP NEXT MULTI BAGGER TODAY 50p4
01/12/201707:35Timbeeerrr back to reality -
23/3/201718:18Physiomics with Charts & News13,676

Add a New Thread

Physiomics (PYC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-12-15 17:22:3211.0090,91010,000.10O
2017-12-15 17:20:1111.2574,3048,359.20O
View all Physiomics trades in real-time

Physiomics (PYC) Top Chat Posts

DateSubject
16/12/2017
08:20
Physiomics Daily Update: Physiomics Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 10.75p.
Physiomics Plc has a 4 week average price of 0.98p and a 12 week average price of 0.93p.
The 1 year high share price is 32p while the 1 year low share price is currently 0.02p.
There are currently 58,785,394 shares in issue and the average daily traded volume is 9,096,955 shares. The market capitalisation of Physiomics Plc is £6,613,356.83.
15/12/2017
10:56
stephen2010: As I posted yesterday evening. Check out ALBA. Huge multibag potential. ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
15/12/2017
08:02
pwhite73: Jenny The MM will stop you buying if they have enough buy orders from professional investors to assure them the share price will be rising beyond your buy price. Conversely the MM will stop you selling if they have enough sell orders from professional investors to assure them the share price will be falling below your sell price. This is because there is a hierarchy in the city. Professional investors take precedence over Joe Blogg PIs like you are I. When PYC issued the qualifying RNS no PIs could get out. With regards to some of the vitriol against me and why I'm not retired instead of posting on a bulletin you can liken it to someone telling their doctor - "if you know so bloody much about the human body why were you off sick last week when I needed to see you urgently. The shares are still spiking due to shorts closing. Be careful if you intend to buy.
14/12/2017
22:22
stephen2010: ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
04/12/2017
09:03
pwhite73: The share price is not rising because of buyers. The MM move the share price to burn whoever they can. Other institutions would have been shorting the stock so the price goes up to burn them. When they've settled they then turn their attention to PI who are still holding profits from last week. As the volumes reduce the share price will return to about 1 - 2p.
03/12/2017
01:38
the stigologist: #PYC Physiomics Share Price : 8p Shares O/S : 57m Mkt Cap : £4.8m Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical trials. This optimisation improves the efficacy of combinations in pre-clinical xenografts. The company is also developing: Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials. Cardiac toxicity prediction service, to predict unwanted toxic side effects of drug candidates early on in the drug discovery process. Drug combinations database, for researchers and clinicians to rapidly access literature data on pre-clinical and clinical regimens and their effects. Physiomics plc works with partners from both small and large pharmaceutical and biotechnology companies since 2002. These include Merck Sharpe & Dohme Corp., Eli Lilly, Merck Serono, Sareum, Institute of Cancer Research, Cancer Research Technology, Cyclacel Pharmaceutical and ValiRx. Fee-for-service, licensing and revenue sharing options are available. On November 28th PYC issued an RNS announcing a €0.5m multi-year deal with Global Pharma company Merck (NYSE:MRK) Mkt Cap $152bn htTps://www.investegate.co.uk/physiomics-plc--pyc-/rns/clinical-project-completion-and-services-agreement/201711280700026248X/ "Physiomics believes that the Agreement represents a significant external validation of its Virtual Tumour technology by Merck." Physiomics are also talking to 58 other potential clients. Several deals are believed to be 'imminent' Further to this Physiomics in January 2017 were awarded a £200k Government grant to work on a Project with Oxford University Cancer specialists to develop a Cancer DSS (Decision Support System) tool. htTps://www.investegate.co.uk/physiomics-plc--pyc-/rns/company-update/201701110700078389T/ "The project is titled "Decision Support Systems For Stratified Cancer Treatment". In line with the Company's strategic objective to explore the personalised medicine market set out in its full year results (published on the 27th October 2016), the objective of the project is to create a prototype decision support system to improve cancer care by helping medical professionals make treatment decisions based on patient specific data." This 12 month project is set to complete in January 2018. Feedback has been promising and the Company believe they can access 'SUBSTANTIAL NON-DILUTIVE FUNDING' from the Government to continue this project. The ex-Founder of Physiomics has been active on the PYC BB this week and stated that he believes the Company could be valued at north of £1 per share. For valuation comparison :- Oncimmune (ONC) Mkt Cap £65m Revenue £0.1m Physiomics (PYC) Mkt Cap £4m Revenue £0.7m
01/12/2017
15:20
rae45: Seen this many times over we private investors buy in to potentially a great business share price over extends every body panicks sells and put there profit and losses else where and in a couple of months the share price is back to the same level or more and we all kick our selves while the institutions laugh at us for being so short sighted .......
01/12/2017
11:11
mayookhp: Momentum Killer...whats the matter with Directors? Why did they issue an RNS..the next day of two...that's was the whole reason share price going north, at least they could do is let the share price recover after horrible consolidations and some ended with un-valuable shares. Are they stupid, they know the reason for consoling the shares, so that they now have 59 mill....what did they expect? Offcourse its going to sky rocket/..so what ?...Nomads and mms just cannot be happy o make people serious dosh.....they are....as long as their bellies are full. Pity , this trading game catches people out, get in and get out with a profit or sit tight on pre 4p shares and hope
30/11/2017
18:57
pwhite73: I don't hear anybody giving me a big round of applause for predicting exactly what would happen here. The RNS has confirmed exactly what I had stated, technically nothing has changed. In my opinion the company is only worth about £750k Now regarding the share price. As previously stated the company has played no part in the meteoric rise it is solely down to the tactics of the MM, professional investors, social media ramping and mug punters. There is nothing like the required amount of shares to go around. The MM will muck about with the share price to sting longs and shorts alike. However in the medium term the share price is heading down for the company is about 20 times overvalued. If you want to know where putting your investment faith in Peter Hoskins can lead to look up a company called EIRX Therapeutics or BillamAG for that matter.
28/11/2017
09:08
pwhite73: Merck have already published findings noting that they have used PYC Virtual Tumor it didn't make a blind bit of difference to the long term company share price and this announcement will make no difference either. To me this reads as the same old same old but with the clever use of wording 'Master Service Agreement'. PYC needs to be signing commercial contracts. naplion Yes I sold out a while back having placed my faith in this company so many times. The trouble is PYC are not a pharmaceutical company as such. They cannot come up with any new drugs. I am not a scientist but if I had to hazard a guess I would say that Virtual Tumor is now out of date considering they have been trying to flog it and still can't secure any contracts. This will slide back be careful if you are buying on this news.
16/10/2017
13:05
walbrock82: I can’t see why this company exist in the market because it’s a company that fails to make significant inroads. Now it reports falling revenue of 9% to £270k, as operating loss increases to half million pounds. Physiomics is burning between £350k-£450k per year in cash and has become a serial share issuer to the small financial institutions. Share price The share price resembles that of Enron. Three or four years ago, this stock trades around 20 to 30 pence. Now, it’s one penny! The continuous placing means there isn’t anything special. Because if there was, then the big boys would have jumped over this and self-funded the operations. Their latest placing to raise over £500k at £0.025 is a discount of 60% or more to the current share price. This means the financial institutions only have confidence in buying at a huge discount and flipping it back to the market for 250% or more in profit. Meanwhile, the shareholders suffer from the continuous decline in the share price. Final Thoughts Physiomics is a big avoid for retail shareholders because the low market capitalisation of £500k has given retail investors the visual image of seeing this rise by 100%-200%. My advice is to avoid the shares, but if there is a probability this company makes £3m-£4m in sales in the next five years and generate a decent profit of £1m, then a market capitalisation of £5m (10-bagger) or £10m (20-bagger). The odds of that happening is rather small. Therefore, this is a speculative investment where the small financial institutions are making the two to three-baggers! Interested in other companies’ updates and results, then click http://bit.ly/2ypK3dk
Physiomics share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20171216 17:00:53